Somatostatin effects on the proteome of the LNCaP cell-line

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1173-1179

  Liu, Zhaoxu ^a,d   Bengtsson, Sofia ^b   Krogh, Morten ^b   Marquez, Marcela ^a   Nilsson, Sten ^a   James, Peter ^b   Aliaya, Ayodele ^c   Holmberg, Anders R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d SHANDONG UNIVERSITY   (China)

Author keywords

LNCaP; Mass spectrometry; Prostatic cancer; Protein expression; Somatostatin; Two dimensional electrophoresis

Indexed keywords

PROTEOME; SOMATOSTATIN; TUMOR PROTEIN;

ARTICLE; CATALYSIS; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION REGULATION; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MITOCHONDRION; PROSTATE TUMOR; PROTEOMICS; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CATALYSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOCHONDRIA; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS; SOMATOSTATIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34447329624     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1173     Document Type: Article

References (44)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 49: 8-31, 1999.
2. Crawford ED: Hormone refractory prostate cancer. Urology 54: S1-S7, 1999.
3. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: TAX 327 Investigators docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
4. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F and Di Silverio F: New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 60: 462-470, 2006.
5. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D and Barrie R: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15: 77-86, 1997.
6. Plonowski A, Schally AV, Nagy A, Sun B and Szepeshazi K: Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 59: 1947-1953, 1999.
7. Sharma K and Srikant CB: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 76: 259-266, 1998.
8. Behe M, Du J, Becker W, Behr T, Angerstein C, Marquez M, Hiltunen J, Nilsson S and Holmberg AR: Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate. Med Oncol 18: 59-64, 2001.
9. Wulbrand U, Feldman M, Pfestroff A, Fehman HC, Du J, Hiltunen J, Marquez M, Arnold R, Westlin JE, Nilsson S and Holmberg AR: A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes. Cancer 94: 1293-1297, 2002.
10. Joensuu TK, Nilsson S, Holmberg AR, Marquez M, Tenhunen M, Saarto T and Joensuu H: Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer. Ann NY Acad Sci 1028: 361-374, 2004.
11. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK and Sandberg AA: The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37: 115-132, 1980.
12. Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ and Mulder E: Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 23: 213-223, 1993.
13. Lin MF, Garcia-Arenas R, Chao YC, Lai MM, Patel PC and Xia XZ: Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch Biochem Biophys 300: 384-390, 1993. (Pubitemid 23225761)
14. Lin MF, Lee MS, Garcia-Arenas R and Lin FF: Differential responsiveness of prostatic acid phosphatase and prostate-specific antigen mRNA to androgen in prostate cancer cells. Cell Biol Int 24: 681-689, 2000.
15. Liu Z, Marquez M, Nilsson S, Holmberg AR and Alaiya AA: Proteomic analysis of a human prostate cancer cell line after incubation with a novel somatostatin14 derivative. Cancer Genomics Proteomics 2: 347-352, 2005.
16. Brevini TA, Bianchi R and Motta M: Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J Clin Endocrinol Metab 77: 626-631, 1993.
17. Franzen B, Linder S, Okuzawa K, Kato H and Auer G: Non-enzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14: 1045-1053, 1993.
18. Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L and Susini C: Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 14: 3911-3928, 2003.
19. Kim R: Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103: 1551-1560, 2005.
20. Kroemer G and Reed JC: Mitochondrial control of cell death. Nat Med 6: 513-519, 2000.
21. Costantini P, Jacotot E, Decaudin D and Kroemer G: Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92: 1042-1053, 2000.
22. Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487, 1999.
23. Lawen A: Apoptosis: an introduction. Bioessays 25: 888-896, 2003.
24. Wood ZA, Schroder E, Harris J and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
25. Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 2005.
26. Baker AM, Oberley LW and Cohen MB: Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32: 229-233, 1997.
27. Shen C and Nathan C: Non-redundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med 8: 95-102, 2002.
28. Parcellier A, Gurbuxani S, Schmitt E, Solary E and Garrido C: Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun 304: 505-512, 2003.
29. Vargas-Roig LM, Gago FE, Tello O, Aznar JC and Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79: 468-475, 1998.
30. Misra UK, Gonzalez-Gronow M, Gawdi G, Hart JP, Johnson CE and Pizzo SV: The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction. J Biol Chem 277: 42082-42087, 2002.
31. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R and Arap W: Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21: 57-63, 2003.
32. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284, 2004.
33. Marklund U, Larsson N, Gradin HM, Brattsand G and Gullberg M: Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 15: 5290-5298, 1996.
34. Mistry SJ and Atweh GF: Stathmin inhibition enhances okadaic acid-induced mitotic arrest: a potential role for stathmin in mitotic exit. J Biol Chem 276: 31209-31215, 2001.
35. Horwitz SB, Shen HJ, He L and Dittmar P: The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J Biol Chem 272: 8129-8132, 1997. (Pubitemid 27147759)
36. Friedrich B, Gronberg H, Landstrom M, Gullberg M and Bergh A: Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27: 102-109, 1995.
37. Arcuri F, Papa S, Carducci A, Romagnoli R, Liberatori S, Riparbelli MG, Sanchez JC, Tosi P and del Vecchio MT: Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60: 130-140, 2004. (Pubitemid 38758578)
38. Li F, Zhang D and Fujise K: Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem 276: 47542-47549, 2001. (Pubitemid 37373139)
39. Cans C, Passer BJ, Shalak V, Nancy-Portebois V, Crible V, Amzallag N, Allanic D, Tufino R, Argentini M, Moras D, Fiucci G, Goud B, Mirande M, Amson R and Telerman A: Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci USA 100: 13892-13897, 2003.
40. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M and Schadendorf D: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21: 3048-3057, 2000.
41. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, Moras D, Amson R and Telerman A: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 101: 15364-15369, 2004.
42. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, De Luca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS and Mak TW: DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273, 2005.
43. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y and Ting JP: Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 63: 6928-6934, 2003. (Pubitemid 37322978)
44. Hod Y: Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem 92: 1221-1233, 2004. (Pubitemid 44264231)